Lupin launches Rufinamide Tablets in United States

05 Dec 2022 Evaluate

Lupin has launched Rufinamide Tablets USP, 200 mg and 400 mg, to market a generic equivalent of Banzel Tablets, 200 mg and 400 mg, of Eisai Inc. Rufinamide Tablets (RLD Banzel) had estimated annual sales of $138 million in the U.S. (IQVIA MAT October 2022). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2176.25 -18.75 (-0.85%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×